Spotlight Medical, a precision medicine tech startup focusing on solving the problem of inadequate cancer therapy, has secured €6.2 ($6.75m) in seed funding to advance its first AI-based prognosis test to the market for cancer clinics.
Co-founded in 2024 by Sylvain Berlemont, Marvin Lerousseau, and Grégoire Gessain, the startup’s seed funding round was led by Kurma Partners and Heal Capital, giving it a financial boost to commercialize AI-backed cancer treatment technology solutions.
Spotlight Medical’s support underscored investors’ confidence in the company’s team and unique technology, which can transform precision oncology. The additional financing will help the company deliver its AI-empowered precision oncology platform to clinics.
According to Sylvain Berlemont, CEO of Spotlight Medical, the new capital will accelerate the company’s mission to leverage the power of AI in analyzing patient data and provide physicians with the medical insights they need to make well-informed treatment decisions.
Spotlight Medical to Commercialize New AI-powered Tests
Spotlight Medical has developed clinical tests utilizing the information contained in patient data to provide actionable insights for personalized cancer treatment.
The company utilizes advanced AI algorithms to provide concrete AI-based solutions, significantly enhancing patient treatment outcomes.
